Related Experiment Videos
[Platelet aggregation in patients with various forms of left ventricular hypertrophy and its changes at long-term
Insights
Platelet aggregation is elevated in patients with left ventricular hypertrophy (LVH) due to essential hypertension (EH) or hypertrophic cardiomyopathy (HTCM). Aspirin treatment effectively reduced this platelet aggregation and silent myocardial ischemia.
Area of Science:
- Cardiology
- Hematology
Background:
- Left ventricular hypertrophy (LVH) is a significant clinical finding in essential hypertension (EH) and hypertrophic cardiomyopathy (HTCM).
- Platelet aggregation (PA) plays a crucial role in cardiovascular pathophysiology.
Purpose of the Study:
- To investigate platelet aggregation (PA) in patients with LVH associated with EH and HTCM.
- To evaluate the therapeutic effects of aspirin on PA in these patient groups.
Main Methods:
- Included 30 males with EH and LVH, 30 males with HTCM, and 10 healthy controls.
- Utilized clinical examination, echocardiography, 24-h ECG and arterial pressure monitoring, exercise tests, and platelet aggregation assays.
- Assessed routine blood biochemical tests.
Main Results:
- Patients with LVH exhibited heightened spontaneous and induced platelet aggregation.
- LVH severity positively correlated with increased PA, independent of arterial pressure or disease duration.
- Patients with silent myocardial ischemia showed more pronounced PA.
- Aspirin administration significantly reduced PA and ST segment depression in both EH and HTCM groups.
Conclusions:
- Platelet aggregation is closely linked to LVH severity and silent myocardial ischemia in both EH and HTCM.
- Aspirin demonstrates efficacy in mitigating abnormal platelet activity and ischemic events in these conditions.
Aim:
To study platelet aggregation (PA) in patients with left ventricular hypertrophy (LVH) in essential hypertension (EH) and hypertrophic cardiomyopathy (HTCM), and to assess aspirin treatment effects.
Material And Methods:
A general clinical examination, echocardiography, 24-h monitoring of ECG and arterial pressure, bicycle exercise, test for platelet aggregation, routine blood biochemical tests were performed in 30 males with EH and LVH, 30 males with HTCM and 10 healthy controls.
Results:
It was found that the patients had high platelet sensitivity to aggregation inductors as well as high spontaneous aggregation. LVH severity correlated positively with activation of spontaneous and induced platelet aggregation. This dependence is unrelated to arterial pressure or the disease duration. Patients with episodes of silent myocardial ischemia had a more pronounced rise in spontaneous and induced platelet aggregation than those without silent ischemia. A long-term administration of aspirin significantly lowered spontaneous and induced platelet aggregation, depression of ST segment. The above changes occurred both in HTCM and in hypertensive patients with LVH.
Conclusion:
Platelet aggregation correlates with severity of LVH and episodes of silent myocardial ischemia both in patients with hypertension, LVH and HTCM.